Gen1044 is an anti-CD3/anti-5T4 bispecific antibody, targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating, antineoplastic and antitumor activities. MW: 145.22 kDa.

Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.

Hpn536 is a tri-specific, T-cell–activating protein-based construct that binds to mesothelin (MSLN)-expressing tumor cells and CD3ϵ on T cells, leading to T-cell activation and potent redirected target cell lysis. It also binds to serum albumin, extending its plasma half-life. HPN536 demonstrates extended half-life in nonhuman primates (NHP) and has the potential to treat mesothelin-expressing solid […]

RO7122290 is a bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. It exhibits potential for treating advanced solid tumors. MW: 177.78 KD.

Gen1042 is a bispecific antibody that targets and conditional stimulates CD40 and 4-1BB to enhance the priming and reactivation of tumor-specific immunity in patients with cancer. It enhances antitumor immunity by modulating DC and T-cell functions and exhibits biological activity in patients with advanced solid tumors. MW: 145.37 KD.

Alnuctamab is a bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. It demonstrates encouraging antitumor activity in patients with relapsed or refractory multiple myeloma. MW: 192.35 KD.

Emb01 is a tetravalent, bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (cMET) on tumor cells, preventing receptor activation and inducing receptor endocytosis, which effectively eliminates these targets on tumor cell surfaces. It demonstrates significant anti-tumor activity in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models, […]

Davutamig is a human bispecific IgG4-kappa antibody that binds to two distinct epitopes of MET, blocking ligand binding and inducing MET internalization and degradation. It demonstrates antineoplastic activity. MW: 144.89 KD.

Mgd010 is a bispecific dual-affinity retargeting (DART®) molecule that targets both the B cell surface proteins CD32B and CD79B, delivering a co-inhibitory signal to dampen B cell activation. It holds potential for treating autoimmune diseases such as rheumatoid arthritis and other inflammatory conditions. MW: 108.77 KD.

Izalontamab is a bispecific IgG antibody that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It demonstrates significant anti-tumor efficacy and acceptable tolerance in xenograft models of colon cancer, head and neck cancer, and esophageal cancer. MW: 197.22 KD.